Literature DB >> 4032401

Remission in rheumatoid arthritis.

F Wolfe, D J Hawley.   

Abstract

Four hundred and fifty-eight patients whose clinical data had been prospectively entered into a rheumatic disease databank were studied for remission utilizing remission criteria of the American Rheumatism Association and criteria modified for chart review. During the period of observation 86 of 458 or 18.8% had at least one remission by investigators' assessment on chart review and 18.1% by application of ARA criteria. Patients were followed for 1131 patient years and remission occupied 97 patient years. For patients achieving remission this period represented 34.5% of their followup duration. The median length of remission was 10 months. Nineteen (18.6) percent of gold treatment courses and 16.7% of penicillamine courses resulted in remission. Fourteen (13.6) percent of patients who never received remittive therapy also had remissions. The ARA Preliminary Criteria for Clinical Remission in Rheumatoid Arthritis displayed a sensitivity of 80.2% and a specificity of 96.2% in this population. In patients receiving remittive therapy, female sex, disease onset before age 60, and early development of erosions were associated with decreased proportion of remission.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4032401

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Rheumatoid Arthritis: Early diagnosis and treatment outcomes.

Authors:  Behzad Heidari
Journal:  Caspian J Intern Med       Date:  2011

Review 2.  Managing the drug treatment of rheumatoid arthritis.

Authors:  Tom D Wilsdon; Catherine L Hill
Journal:  Aust Prescr       Date:  2017-04-03

3.  Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria.

Authors:  Shadi H Shahouri; Kaleb Michaud; Ted R Mikuls; Liron Caplan; Timothy S Shaver; James D Anderson; David N Weidensaul; Ruth E Busch; Shirley Wang; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2011-11

4.  Utility of disease modifying antirheumatic drugs in "sawtooth" strategy. A prospective study of early rheumatoid arthritis patients up to 15 years.

Authors:  T Sokka; P Hannonen
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

5.  Prospidine versus methotrexate pulse in highly active rheumatoid arthritis: a controlled 6-month clinical trial.

Authors:  E V Benenson; O B Timina
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

6.  Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?

Authors:  H A Capell; D R Porter; R Madhok; J A Hunter
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

7.  HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments.

Authors:  J R O'Dell; B S Nepom; C Haire; V H Gersuk; L Gaur; G F Moore; W Drymalski; W Palmer; P J Eckhoff; L W Klassen; S Wees; G Thiele; G T Nepom
Journal:  Ann Rheum Dis       Date:  1998-04       Impact factor: 19.103

8.  Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

9.  A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.

Authors:  S M M Verstappen; G A van Albada-Kuipers; J W J Bijlsma; A A M Blaauw; Y Schenk; H C M Haanen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-05-06       Impact factor: 19.103

Review 10.  Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection.

Authors:  C G Jackson; H J Williams
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.